OTC · Financial Statements

Bangkok Dusit Medical Services Public Company Limited (BDUUY) Financial Statements

$23.41 OTC: BDUUY Market Cap $9.30B

Bangkok Dusit Medical Services Public Company Limited most recently reported annual revenue of $106.9B, net profit of $15.2B. Revenue grew at an average annual rate of 9.4% over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Bangkok Dusit Medical Services Public Company Limited: Revenue rose from $68.0B in 2016 to $106.9B in 2025, a change of +57.2% over 9 years; net profit was positive in all 10 reported years; operating margin was broadly flat at about 16.6%; the most recent year shows net profit of $15.2B.

Income Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Revenue$68.0B$71.9B$78.4B$82.7B$68.1B$74.5B$91.9B$100.9B$107.9B$106.9B
Operating Expenses$56.6B$60.2B$64.9B$69.5B$57.1B$63.2B$74.9B$81.9B$87.4B$89.2B
Operating Profit$11.3B$11.8B$13.5B$13.2B$11.0B$11.2B$17.0B$18.9B$20.5B$17.7B
Operating Margin16.7%16.4%17.3%15.9%16.1%15.1%18.5%18.8%19.0%16.6%
Other Income$-651.0M$2.8B$-1.1B$204.0M$-559.0M$-634.0M$-510.0M$-284.0M$-183.0M$1.5B
Interest$881.0M$1.5B$1.2B$929.0M$871.0M$728.0M$632.0M$547.0M$433.0M$342.0M
Depreciation$4.8B$5.2B$5.3B$5.7B$6.4B$6.3B$6.0B$5.8B$6.1B$6.6B
Profit Before Tax$10.7B$13.1B$12.4B$19.9B$10.4B$10.6B$16.5B$18.7B$20.3B$19.2B
Tax$18.0M$19.5M$22.1M$19.5M$26.4M$19.9M$19.6M$20.1M$18.6M$18.4M
Net Profit$8.4B$10.2B$9.2B$15.5B$7.2B$7.9B$12.6B$14.4B$16.0B$15.2B
EPS$21.60$26.40$23.60$39.60$18.00$20.00$31.60$36.00$40.40$38.00
Dividend Payout0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

MetricJun '23Sep '23Dec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26
Revenue$24.1B$26.4B$26.3B$26.6B$25.7B$28.2B$27.4B$28.1B$26.7B$28.2B$27.9B$29.1B
Operating Expenses$20.0B$21.3B$21.2B$21.6B$21.4B$22.5B$22.1B$22.5B$22.2B$22.8B$23.9B$24.1B
Operating Profit$4.1B$5.1B$5.2B$5.0B$4.3B$5.6B$5.3B$5.6B$4.5B$5.5B$4.0B$5.0B
Operating Margin16.9%19.4%19.6%18.7%16.6%19.9%19.4%20.0%16.9%19.3%14.3%17.2%
Interest$134.0M$122.0M$126.0M$113.0M$111.0M$102.0M$108.0M$97.0M$96.0M$79.0M$82.0M$76.0M
Profit Before Tax$4.0B$5.1B$5.1B$5.2B$4.2B$5.6B$5.3B$5.6B$4.5B$5.4B$4.5B$5.4B
Tax$20.4M$20.2M$20.3M$19.9M$17.9M$20.7M$15.9M$19.4M$18.8M$17.9M$17.5M$19.4M
Net Profit$3.1B$3.9B$4.0B$4.1B$3.3B$4.2B$4.3B$4.3B$3.5B$4.3B$3.6B$4.2B
EPS$7.60$9.60$10.00$10.40$8.40$10.80$10.80$10.80$8.80$10.80$9.20$10.40

Over the 10 years reported for Bangkok Dusit Medical Services Public Company Limited, borrowings decreased from $31.9B in 2016 to $17.5B in 2025, cash stood at $6.3B in the latest year, shareholders' equity was $1.6B, current assets covered current liabilities 0.98 times.

Balance Sheet — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Total Assets$106.9B$122.6B$133.5B$133.7B$136.1B$128.5B$141.5B$143.6B$151.5B$158.0B
Current Assets$12.6B$14.4B$15.2B$16.3B$30.0B$24.4B$27.8B$23.5B$23.7B$23.1B
Cash$4.2B$5.1B$5.0B$4.7B$19.7B$10.9B$12.7B$7.8B$7.4B$6.3B
Inventory$1.5B$1.7B$1.8B$1.8B$1.9B$2.0B$2.2B$2.4B$2.6B$3.4B
Receivables$6.0B$6.7B$7.1B$8.5B$6.9B$8.8B$10.2B$11.3B$12.0B$12.0B
Fixed Assets$56.5B$71.6B$74.5B$78.4B$84.6B$82.6B$91.5B$97.3B$104.0B$109.5B
Capital Work in Progress$0$0$0$0$0$0$0$0$0$0
Investments$17.2B$17.0B$24.0B$19.0B$2.7B$3.2B$4.3B$3.8B$3.8B$4.6B
Other Assets$16.9B$17.5B$17.5B$17.5B$17.5B$17.5B$17.5B$17.5B$17.5B$17.5B
Total Liabilities$48.6B$56.8B$60.1B$46.5B$44.6B$40.7B$47.8B$44.7B$47.6B$48.0B
Current Liabilities$17.9B$13.4B$28.5B$19.3B$11.2B$15.9B$20.6B$18.4B$22.0B$23.6B
Borrowings$31.9B$39.3B$39.9B$24.4B$24.2B$18.8B$23.6B$18.1B$18.4B$17.5B
Other Liabilities$16.7B$17.4B$20.1B$22.1B$20.3B$21.9B$24.2B$26.6B$29.2B$30.5B
Equity$1.5B$1.5B$1.6B$1.6B$1.6B$1.6B$1.6B$1.6B$1.6B$1.6B
Reserves$55.7B$63.1B$70.3B$83.8B$87.9B$83.8B$89.9B$95.4B$100.0B$105.9B

For Bangkok Dusit Medical Services Public Company Limited, operating cash flow was positive in 10 of 10 reported years; free cash flow in the latest year was $12.5B; free cash flow was positive in 9 of 10 years; financing activities used $742.0M in the latest year, which covers debt repayment, dividends and buybacks.

Cash Flow Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Operating Cash Flow$12.4B$10.9B$14.8B$14.5B$11.7B$14.6B$20.3B$20.8B$23.0B$22.5B
Investing Cash Flow$-18.9B$-27.8B$-21.1B$-5.2B$5.7B$-9.1B$-11.0B$-16.1B$-23.1B$-20.3B
Financing Cash Flow$-386.0M$-153.0M$-238.0M$-263.0M$-246.0M$-187.0M$-2.0B$-687.0M$-292.0M$-742.0M
Net Cash Flow$-1.3B$874.0M$-58.0M$-337.0M$15.0B$-8.7B$1.7B$-4.9B$-422.0M$-472.0M
Free Cash Flow$3.5B$-4.7B$7.1B$6.6B$5.0B$10.2B$15.2B$12.5B$11.3B$12.5B

Valuation & Return Ratios

MetricValue
PEG Ratio-5.10
EV / EBITDA12.24
FCF Yield4.10%
Quick Ratio0.98
Interest Coverage55.58
Return 1Y-23.62%
Return 3Y-13.53%
Return 5Y18.71%

Bangkok Dusit Medical Services Public Company Limited (BDUUY) financials — frequently asked questions

What is Bangkok Dusit Medical Services Public Company Limited's annual revenue?

Bangkok Dusit Medical Services Public Company Limited (BDUUY) reported annual revenue of $106.9B in its most recent fiscal year.

What is Bangkok Dusit Medical Services Public Company Limited's net profit?

Bangkok Dusit Medical Services Public Company Limited (BDUUY) reported net profit of $15.2B in its most recent fiscal year.

What is BDUUY EV/EBITDA?

Bangkok Dusit Medical Services Public Company Limited's enterprise value to EBITDA (EV/EBITDA) ratio is 12.24.

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksAll stock screens
BDUUY Overview BDUUY Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.